From evidence strategy to submission-ready dossier in one continuous workflow
CLEVAIR-HTA has been built specifically to address EU HTA Regulation 2021/2282 and support the JCA process from evidence strategy to submission-ready dossier in one continuous workflow.
Built for pharma teams that need workflow fit, expert control, and traceable execution across comparator work, evidence operations, drafting, and review.
EU HTA Regulation 2021/2282 creates an execution challenge, not just a document challenge
The regulation was meant to streamline assessment. For many teams, it is creating a new execution challenge instead: more coordination pressure across evidence, drafting, review, and delivery.
Built specifically for EU HTA and JCA execution
CLEVAIR-HTA helps teams keep comparator logic, evidence, drafting, and review connected from early strategy through submission-ready output.
Keep comparator logic, evidence, drafting, and review connected in one execution model.
Reduce downstream rework by carrying decisions forward instead of rebuilding the story by hand.
Make ownership, comments, and approvals visible throughout review.
Move validated evidence into submission-ready output without losing traceability.
Move faster without losing control, traceability, or review discipline
Pharma teams trust CLEVAIR when the workflow is transparent, the review process is visible, and the evidence stays traceable throughout.
See whether CLEVAIR fits your current HTA workflow
Show us where your team is facing delay, duplication, comparator complexity, evidence pressure, or review friction. We will tailor the discussion around the part of your workflow that needs the most support first.